Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. HOOD
6. QCOM
7. ACN
8. AZN
9. ROIV
10. AAPL

Go back to Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
(NASDAQ: BMEA) Delayed: 1.93 -0.1 (4.93%)
Previous Close $2.03    52 Week High $ 
Open $2.00    52 Week Low $ 
Day High $2.07    P/E N/A 
Day Low $1.89    EPS $ 
Volume 1,852,882